Although no primary resistance mutations were identified for HCV protease inhibitors or nucleoside analogues, mutations C316Y/N and V499A conferring resistance to some non-nucleoside analogues were found in 6% and 51% of G1 patients, respectively. Conclusions: Natural DAA resistance-associated mutations are frequently seen in HIV-HCV-coinfected individuals. Changes polV499A and prQ80K seem to be natural polymorphisms and their effect on treatment outcomes warrants further examination. However, drug resistance testing in HCV drug-naive individuals coinfected with HIV currently does not seem to be warranted before using HCV protease inhibitors and nucleoside analogues. More information is needed for HCV non-nucleoside analogues.
Oral drugs designed to inhibit the HCV serine protease and the RNA-dependent RNA polymerase have recently entered the late phases of clinical development [1] [2] [3] [4] . Overcoming toxicities and resistance are among the main challenges in HCV drug development. Primary resistance to these compounds in HCVmonoinfected patients seems to be low, in the range of 0.2-2.8%, with significant differences between HCV genotypes/subtypes and when considering distinct compounds [5] [6] [7] [8] [9] [10] .
There is scarce information on the rate of these changes in the HIV-infected population. Hypothetically, a larger HCV variability due to immunodeficiency [11, 12] and a potential effect of HIV antiretroviral drugs on HCV enzymes [13] could increase the rate of primary HCV drug resistance-associated mutations in HIV-HCV-coinfected patients. If significant rates of primary resistance mutations to these agents are recognized (for example, >5-10%), HCV drug resistance testing could be advisable before these compounds are prescribed, as it is currently recommended for antiretroviral drugs [14] .
Methods
All individuals newly diagnosed with HIV-1 at several clinics in Madrid between January 2000 and February 2010 were tested for serum HCV antibodies using a commercial enzyme immunoassay. HCV seroreactive specimens were further tested for serum HCV RNA using either the Abbott real-time HCV quantitative assay (Abbott Laboratories, Madrid, Spain) or Versant The NS3/NS4A protease and NS5B polymerase genes were sequenced in HCV genotype 1 (G1) patients. Viral RNA was extracted from plasma samples using a QUIamp viral RNA mini extraction kit (Qiagen, Hamburg, Germany) following the manufacturer's instructions. Both regions were amplified using a reverse transcriptase (RT) nested PCR using specific primers for subtype 1a and 1b. The primers used for the amplification of the NS3/NS4A protease subtype 1a were: PR1aEF1 (5′-CGA GAT CTG GCC GTG GCTG-3′), PR1aER1 (5′-GAC TGT CTG GGT GAC ACA CG-3′), PR1aEF2 (5′-TGA CAT AAT AAT TTG TGA CG-3′) and PR1aER2 (5′-GTG ACG GCA GCT GTA AAA GC-3′) as outer primers, and PR1aIF1 (5′-GTG CGG TGA CAT CAT CAA CG-3′), PR1aIR1 (5′-CGA GCT CGT CGC ACT TCT TC-3′), PR1aIF2 (5′-TTG ACC AAG CAG AGA CTG CG-3′) and PR1aIR2 (5′-GTC TGC AGG AGG CCG AGG GC-3′) as inner primers. The primers used for the amplification of the NS3/NS4A protease subtype 1b were: PR1bEF1 (5′-GGG CTC ATY CGT GCA TGC ATG-3′), PR1bER1 (5′-CGT CGT CTC AAT GGT GAA GG-3′), PR1bEF2 (5′-CCC TTC TAT GGC AAA GCC AT-3′) and PR1bER2 (5′-TTC CAC ATG TGC TTC GCCC-3′) as outer primers, and PR1bINF1 (5′-GAG ACC AAG RTC ATC ACC TGG-3′), PR1bINR1 (5′-CGA CTG TCT GGG TGA CAC ATG-3′), PR1bINF2 (5′-CTY GAT GTG TCC GTC ATA CC-3′) and PR1bINR2 (5′-GCC TCC GCT TGC TTG GTG GC-3′) as inner primers.
The primers used for the amplification of the NS5B polymerase subtype 1a were: POL1aEF1 (5′-CTT CCA TGC CCC CCC TGG AG-3′), POL1aER1 (5′-CGG AGT ACC TGG TCA TAGC-3′), POL1aEF2 (5′-GAG AGG CTT TAT GTT GGG GG-3′) and POL1aER2 (5′-CAG CTA GCC GTG ACT AGG GC-3′) as outer primers, and POL1aIF1 (5′-GGA TCC GGA TCT CAG CGA CG-3′), POL1aIR1 (5′-CTT TCA CAG ATA ACG ACTA-3′), POL1aIF2 (5′-GCT GTG GTA ACA CCC TCA CTTG-3′) and POL1aIR2 (5′-ACA GGA AAT GGC CTA AGA GG-3′) as inner primers. The primers used for the amplification of the NS5B polymerase subtype 1b were: POL1BEF1 (5′-CCG TGT CTT CTG CCT TGGC-3′), POL1bER1 (5′-GTA CCT AGT CAT AGC CTC CG-3′), POL1bEF2 (5′-CAT ATG ACA CCC GCT GTT TTG-3′) and POL1bER2 (5′-CTA GGG CTA AGA TGG AGCC-3′) as outer primers, and POL1bIF1 (5′-CCC CCC CTT GAG GGR GAGC-3′), POL1bIR1 (5′-CAC AGA TAA CGA CAA GGT CG-3′), POL1bIF2 (5′-GCC ATA AGG TCG CTC ACA GA-3′) and POL1-bIR2 (5′-CTA TTG GCC TGG AGT GTT TAGC-3′) as inner primers. Conditions for the RT-PCRs were 50°C for 30 min, 94°C for 15 min, 40 cycles at 94°C for 35 s, 53-55°C for 30 s and 72°C for 1 min and 30 s, and a final extension at 72°C for 10 min. For the nested PCR the conditions were 94°C for 15 min, 40 cycles at 94°C for 35 s, 53-55°C for 35 s, and 72°C for 1 min and 30 s, and a final extension at 72°C for 10 min. PCR amplicons were purified using the High Pure PCR Product Purification kit (Roche, Mannheim, Germany) and directly sequenced using the ABI PRISM 3100 Genetic Analyser using the ABI PRISM Rhodamine Terminator reaction kit (Applied Biosystems, Foster City, CA, USA) and inner primers for each genetic region. Sequences were aligned and analysed for mutations using the SeqScape V2.5 software (Applied Biosystems).
Results
A total of 1,684 newly diagnosed HIV-1 individuals were identified during the 10-year study period. Serum HCV RNA was positive in 141 (8.4%). Median viral load was 5.6 log IU/ml in viraemic patients. Approximately 20% of HCV-seropositive specimens were aviraemic, reflecting spontaneous clearance. In the remaining viraemic HCV population, males were 74% and their median age was 40 years old. Transmission route had been intravenous drug use in 46%, homosexual relationships in 27%, heterosexual contacts in 22%, and was either other or unknown in the remaining 5%. The origin of the coinfected population was as follows: 63% were native Spaniards, 13% Latin-Americans, 13% Sub-Saharan Africans, 9% originated in other European countries and the remaining 2% came from other regions. As expected in newly diagnosed individuals, all were antiretroviral-naive. The median CD4 + T-cell count in our coinfected population was 387 cells/ mm 3 (IQR 182-689) and the median plasma HIV RNA was 4.6 log copies/ml. Overall, 37% of patients had a CD4 + T-cell count <200 cells/mm 3 . The distribution of HCV genotypes was as follows: 67 G1 (58%), being 43 1a, 20 1b and 4 untypable, 24 G4 (21%), 22 G3 (19%) and 3 G2 (2%). Complete sequences from G1 patients could be obtained for 55 proteases and 47 polymerases. The remaining samples did not amplify most likely due to low HCV RNA levels and/or sequence diversity in primer binding regions. For 6 specimens, there was not enough volume for further virological characterization. Drug resistance mutations examined at the HCV protease and polymerase were those recorded at the last updated list from Sarrazin and Zeuzem [15] , which considers 9 positions at the NS3/4A protease and 15 at the NS5B polymerase. Two changes were found at the protease: Q80K (8 G1a and 1 G1b) and V55A (2 G1a). Table 1 records the results of this study in comparison with findings from others [5, 6] and the GenBank database. Three changes were found at the polymerase: C316N (2 G1b), C316Y (1 G1a) and V499A (21 G1a and 3 G1b). Altogether 62% of HIV-HCV-coinfected patients with G1a and 30% with G1b harboured ≥1 HCV drug resistance-associated change. No primary drug resistance mutations were identified for HCV protease inhibitors or nucleoside analogues. By contrast, primary resistance changes for some HCV nonnucleoside analogues were found; mutation C316Y/N at the polymerase, which confers resistance to pockets 3 and 4 non-nucleoside analogues (for example, HCV-796, ANA-598 and ABT-333) was found in 6% of G1 patients. Mutation V499A, which may compromise the activity of thumb non-nucleoside analogues (for example, MK-3281 and BI-1941) was found in 51% of G1 patients, behaving as a natural polymorphism, particularly common in HCV subtype 1a.
Discussion
This is one of the first studies providing information about the rate of primary drug resistance to direct acting antivirals (DAA) against HCV in HIV-coinfected individuals. From an initial population of 1,684 newly diagnosed HIV-1 individuals during the last 10 years in several HIV clinics in Madrid, Spain, serum HCV RNA was positive in 141 (8.4%) of them. Approximately 20% of HCV-seropositive specimens were aviraemic, reflecting spontaneous clearance, a rate which is in agreement with findings from other recent larger studies performed in HIV-infected individuals [16] .
Sequencing of the HCV protease and polymerase coding regions from plasma of HCV G1 patients were successful in 55 and 47 of cases, respectively. Overall, our results suggest that mutations associated with resistance to either HCV protease or polymerase inhibitors are relatively common in HIV-HCV-coinfected individuals naive for DAA. However, primary resistance changes at the protease, as at codon 155, which have been associated in vivo with diminished viral response to telaprevir or boceprevir [15] were not recognized. In contrast, polC316Y/N changes, which have been associated with primary resistance to non-nucleosides HCV-796, ANA-598 and ABT-333 in vivo [15] were found in 1 G1a and 2 G1b patients. Interestingly, changes prQ80K and polV499A seem to be natural polymorphisms given their high prevalence (16% and 51%, respectively) in the study population; in addition, their effect on treatment outcomes using anti-HCV oral drugs warrants further examination. It should be highlighted that a valine at position 499 in the polymerase was more common than alanine in HCV subtype 1a, acting as the consensus amino acid, in contrast with HCV subtype 1b. These findings are somewhat similar to those reported by Gaudieri et al. [7] , who tested samples from Australia, Switzerland and the United Kingdom (42% belonging to HIV-HCV-coinfected individuals), and found polC316Y/F/s and polV499A in only 2% and 75% of G1 patients, respectively. HCV subtype 1a represented 77% of their G1 population. Clearly, our results suggesting a higher rate of primary resistance mutations to some HCV non-nucleoside analogues in HIV-coinfected individuals warrants further investigation. Our results point out that it is the relative proportion of HCV subtype 1a versus 1b instead Current study Resistance-associated mutation GenBank database Bartels et al. [5] Kuntzen et al. [6] Gaudieri et al. [7] (all HIV-HCV-coinfected) of HIV coinfection that mainly influences the rate of primary HCV drug resistance changes. In summary, we did not find any evidence for an overall increased rate of primary drug resistance mutations in HIV-HCV-coinfected individuals, taking as reference the data reported in HCV-monoinfected individuals [5, 6] . Therefore, baseline HCV drug resistance testing does not seem to be warranted before prescription of the new HCV protease inhibitors and nucleoside analogues in this population. However, more information is needed regarding the potential effect of natural polymorphisms on any of the five classes of HCV nonnucleoside analogues, as our data suggest an increased rate of some resistance changes in the coinfected population compared to HCV-monoinfected individuals. It may be the case that rather than HIV coinfection itself, it is the relative proportion of HCV subtypes 1a versus 1b in a given population that largely determines the rate of primary HCV drug resistance. Further studies testing larger populations and including patients with prior exposure to antiretroviral therapy are warranted.
